Pediatric reference intervals for lipids and apolipoproteins on the VITROS 5,1 FS Chemistry System

Clinical Biochemistry

Volumn 39, Issue 10, 2006, Pages 978-983

  Yip, Paul M ^a,b   Chan, Man Khun ^a   Nelken, Joanna ^a   Lepage, Nathalie ^c   Brotea, George ^d   Adeli, Khosrow ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d Ortho Clinical Diagnostics Inc   (United States)

Author keywords

Adolescents; Apolipoprotein; Cardiovascular risk factor; Cholesterol; HDL cholesterol; LDL cholesterol; Metabolic syndrome; Newborns; Pediatric chemistry; Triglycerides

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ADULTHOOD; ANALYTICAL EQUIPMENT; ARTICLE; CARDIOVASCULAR RISK; CHILD; FEMALE; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; INFANT; MALE; NEWBORN; OUTPATIENT; PLASMA; PRIORITY JOURNAL; PUBERTY; REFERENCE VALUE; SERUM; TURBIDITY;

ADOLESCENT; APOLIPOPROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIPIDS; MALE; REFERENCE VALUES;

EID: 33749030463     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.06.012     Document Type: Article

References (39)

1. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
3. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
4. American Academy of Pediatrics. National cholesterol education program: report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89 (1992) 525-584
5. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
6. Troiano R.P., and Flegal K.M. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics 101 (1998) 497-504
7. Fagot-Campagna A., Pettitt D.J., Engelgau M.M., Burrows N.R., Geiss L.S., Valdez R., et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J. Pediatr. 136 (2000) 664-672
8. Daniels S.R., Arnett D.K., Eckel R.H., Gidding S.S., Hayman L.L., Kumanyika S., et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 111 (2005) 1999-2012
9. Goran M.I., and Gower B.A. Abdominal obesity and cardiovascular risk in children. Coron. Artery Dis. 9 (1998) 483-487
10. Berenson G.S., Srinivasan S.R., Bao W., Newman III W.P., Tracy R.E., and Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338 (1998) 1650-1656
11. Raitakari O.T., Porkka K.V., Ronnemaa T., Knip M., Uhari M., Akerblom H.K., et al. The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study. Diabetologia 38 (1995) 1042-1050
12. Strong J.P., Malcom G.T., McMahan C.A., Tracy R.E., Newman3rd W.P., Herderick E.E., et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281 (1999) 727-735
13. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
14. Steinberger J., Moran A., Hong C.P., Jacobs Jr. D.R., and Sinaiko A.R. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J. Pediatr. 138 (2001) 469-473
15. S. Mansoub, M.K. Chan, K. Adeli, Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome. Clin Biochem 2006;39:569--87.
16. Duncan I.W., Mather A., and Cooper G.R. The procedure for the proposed cholesterol reference method (1982), Centers for Disease Control, Atlanta, GA
17. Cole T.G., Klotzach S.G., and McNamara J.R. Measurement of triglyceride concentration. In: Dominiczak M.K. (Ed). Handbook of lipoprotein testing. 2nd ed. (2000), AACC Press, Washington DC 207-219
18. Fossati P., and Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 28 (1982) 2077-2080
19. Kimberly M.M., Leary E.T., Cole T.G., and Waymack P.P. Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin. Chem. 45 (1999) 1803-1812
20. Bachorik P.S., and Ross J.W. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin. Chem. 41 (1995) 1414-1420
21. Hicks J.M., Bailey J., Beatly J., Bjorn S., and Soldin S.J. Pediatric reference ranges for cholesterol. Clin. Chem. 42 (1996) S308
22. Lockitch G., Halstead A.C., Albersheim S., MacCallum C., and Quigley G. Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin. Chem. 34 (1988) 1622-1625
23. Wennlof A.H., Yngve A., Nilsson T.K., and Sjostrom M. Serum lipids, glucose and insulin levels in healthy schoolchildren aged 9 and 15 years from Central Sweden: reference values in relation to biological, social and lifestyle factors. Scand. J. Clin. Lab. Invest. 65 (2005) 65-76
24. Kottke B.A., Moll P.P., Michels V.V., and Weidman W.H. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin. Proc. 66 (1991) 1198-1208
25. Jagarinec N., Flegar-Mestric Z., Surina B., Vrhovski-Hebrang D., and Preden-Kerekovic V. Pediatric reference intervals for 34 biochemical analytes in urban school children and adolescents. Clin. Chem. Lab. Med. 36 (1998) 327-337
26. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
27. Gidding S.S., Dennison B.A., Birch L.L., Daniels S.R., Gilman M.W., Lichtenstein A.H., et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 112 (2005) 2061-2075
28. Eberly L.E., Stamler J., and Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch. Intern. Med. 163 (2003) 1077-1083
29. van Wijk J.P., van Oostrom A.J., and Castro Cabezas M. Normal ranges of non-fasting triglycerides in healthy Dutch males and females. Clin. Chim. Acta 337 (2003) 49-57
30. Caudill S.P., Cooper G.R., Smith S.J., and Myers G.L. Assessment of current National Cholesterol Education Program guidelines for total cholesterol triglyceride, HDL-cholesterol, and LDL-cholesterol measurements. Clin. Chem. 44 (1998) 1650-1658
31. Baroni S., Scribano D., Valentini P., Zuppi C., Ranno O., and Giardina B. Serum apolipoprotein A1, B, CII, CIII, E, and lipoprotein (a) levels in children. Clin. Biochem. 29 (1996) 603-605
32. Gozlan O., Gross D., and Gruener N. Lipoprotein levels in newborns and adolescents. Clin. Biochem. 27 (1994) 305-306
33. Soldin O.P., Bierbower L.H., Choi J.J., Thompson-Hoffman S., and Soldin S.J. Serum iron, ferritin, transferrin, total iron binding capacity, hs-CRP, LDL cholesterol and magnesium in children; new reference intervals using the Dade Dimension Clinical Chemistry System. Clin. Chim. Acta 342 (2004) 211-217
34. Horn P.S., and Pesce A.J. Reference intervals: an update. Clin. Chim. Acta 334 (2003) 5-23
35. Stan S., Levy E., Delvin E.E., Hanley J.A., Lamarche B., O'Loughlin J., et al. Distribution of LDL particle size in a population-based sample of children and adolescents and relationship with other cardiovascular risk factors. Clin. Chem. 51 (2005) 1192-1200
36. Kwiterovich Jr. P.O., Coresh J., Smith H.H., Bachorik P.S., Derby C.A., and Pearson T.A. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am. J. Cardiol. 69 (1992) 1015-1021
37. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med. 325 (1991) 373-381
38. Bachorik P.S., Lovejoy K.L., Carroll M.D., and Johnson C.L. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin. Chem. 43 (1997) 2364-2378
39. Schaefer E.J., Lamon-Fava S., Cohn S.D., Schaefer M.M., Ordovas J.M., Castelli W.P., et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J. Lipid Res. 35 (1994) 779-792